TY - JOUR
T1 - β-lactam precision dosing in critically ill children
T2 - Current state and knowledge gaps
AU - Tang Girdwood, Sonya
AU - Pavia, Kathryn
AU - Paice, Kelli
AU - Hambrick, H. Rhodes
AU - Kaplan, Jennifer
AU - Vinks, Alexander A.
N1 - Publisher Copyright:
Copyright © 2022 Tang Girdwood, Pavia, Paice, Hambrick, Kaplan and Vinks.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - There has been emerging interest in implementing therapeutic drug monitoring and model-informed precision dosing of β-lactam antibiotics in critically ill patients, including children. Despite a position paper endorsed by multiple international societies that support these efforts in critically ill adults, implementation of β-lactam precision dosing has not been widely adopted. In this review, we highlight what is known about β-lactam antibiotic pharmacokinetics and pharmacodynamics in critically ill children. We also define the knowledge gaps that present barriers to acceptance and implementation of precision dosing of β-lactam antibiotics in critically ill children: a lack of consensus on which subpopulations would benefit most from precision dosing and the uncertainty of how precision dosing changes outcomes. We conclude with opportunities for further research to close these knowledge gaps.
AB - There has been emerging interest in implementing therapeutic drug monitoring and model-informed precision dosing of β-lactam antibiotics in critically ill patients, including children. Despite a position paper endorsed by multiple international societies that support these efforts in critically ill adults, implementation of β-lactam precision dosing has not been widely adopted. In this review, we highlight what is known about β-lactam antibiotic pharmacokinetics and pharmacodynamics in critically ill children. We also define the knowledge gaps that present barriers to acceptance and implementation of precision dosing of β-lactam antibiotics in critically ill children: a lack of consensus on which subpopulations would benefit most from precision dosing and the uncertainty of how precision dosing changes outcomes. We conclude with opportunities for further research to close these knowledge gaps.
UR - http://www.scopus.com/inward/record.url?scp=85144073337&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144073337&partnerID=8YFLogxK
U2 - 10.3389/fphar.2022.1044683
DO - 10.3389/fphar.2022.1044683
M3 - Short survey
AN - SCOPUS:85144073337
SN - 1663-9812
VL - 13
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 1044683
ER -